Clinical Trials Directory

Trials / Conditions / KRAS G12V

KRAS G12V

8 registered clinical trials studyying KRAS G12V — 4 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingTCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
NCT07342738
Sun Yat-sen UniversityEARLY_Phase 1
RecruitingBBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)Phase 1
Not Yet RecruitingRE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors
NCT06545201
Henan Cancer HospitalPhase 1
Active Not RecruitingPhase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Meta
NCT06105021
Affini-T Therapeutics, Inc.Phase 1 / Phase 2
RecruitingPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924
Institut de Recherches Internationales ServierPhase 1 / Phase 2
Active Not RecruitingA Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors
NCT05726864
Elicio TherapeuticsPhase 1 / Phase 2
Active Not RecruitingCAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
NCT05631899
Chinese PLA General HospitalPhase 1
AvailableExpanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
NCT07083479
Elicio Therapeutics—